SEARCH

SEARCH BY CITATION

References

  • 1
    Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, et al. Heart disease and stroke statistics 2011 update. Circulation 2011; 123: e18209.
  • 2
    Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA. Primary and secondary prevention of cardiovascular disease. Chest 2012; 141: e637S68S.
  • 3
    Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 236372.
  • 4
    von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 2740.
  • 5
    Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 6126.
  • 6
    von Hundelshausen P, Weber KSC, Huo Y, Proudfoot AEI, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 17727.
  • 7
    Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A 1981; 78: 45847.
  • 8
    Lane DA, Ireland H, Wolff S, Ranasinghe E, Dawes J. Detection of enhanced in vivo platelet alpha-granule release in different patient groups – comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays. Thromb Haemost 1984; 52: 1837.
  • 9
    Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, Hiss E, Ziporen L, Aviram M, Cines D, Poncz M, Higazi AA. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 618793.
  • 10
    Preston RJ, Tran S, Johnson JA, Ni AF, Harmon S, White B, Smith OP, Jenkins PV, Dahlback B, O’Donnell JS. Platelet factor 4 impairs the anticoagulant activity of activated protein C. J Biol Chem 2009; 284: 586975.
  • 11
    Sachais BS, Kuo A, Nassar T, Morgan J, Kariko K, Williams KJ, Feldman M, Aviram M, Shah N, Jarett L, Poncz M, Cines DB, Higazi AA. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 361322.
  • 12
    Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, van der Bom JG. High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. J Thromb Haemost 2010; 8: 90613.
  • 13
    Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007; 27: 92935.
  • 14
    Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol 2006; 48: 15919.
  • 15
    Sobel M, Salzman EW, Davies GC, Handin RI, Sweeney J, Ploetz J, Kurland G. Circulating platelet products in unstable angina pectoris. Circulation 1981; 63: 3006.
  • 16
    Taomoto K, Asada M, Kanazawa Y, Matsumoto S. Usefulness of the measurement of plasma beta-thromboglobulin (beta-TG) in cerebrovascular disease. Stroke 1983; 14: 51824.
  • 17
    Rasi V, Ikkala E, Torstila I. Plasma thromboglobulin in acute myocardial infarction. Thromb Res 1982; 25: 20312.
  • 18
    van der Krabben MD, Rosendaal FR, van der Bom JG, Doggen CJM. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008; 6: 7205.
  • 19
    van Bladel ER, Roest M, De Groot PG, Schutgens RE. Up-regulation of platelet activation in hemophilia A. Haematologica 2011; 96: 88895.
  • 20
    Berent R, Auer J, Franklin B, Schmid P, von Duvillard SP. Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. The American Journal of Cardiology 2011; 108: 64450.
  • 21
    Andrassy K, Deppermann D, Ritz E, Koderisch J, Seelig H. Different effects of renal failure on beta-thromboglobulin and high affinity platelet factor 4 (HA-PF4)-concentrations. Thromb Res 1980; 18: 46975.